• Skip to content (access key 1)
  • Skip to search (access key 7)
FWF — Austrian Science Fund
  • Go to overview page Discover

    • Research Radar
    • Discoveries
      • Emmanuelle Charpentier
      • Adrian Constantin
      • Monika Henzinger
      • Ferenc Krausz
      • Wolfgang Lutz
      • Walter Pohl
      • Christa Schleper
      • Anton Zeilinger
    • scilog Magazine
    • Awards
      • FWF Wittgenstein Awards
      • FWF START Awards
    • excellent=austria
      • Clusters of Excellence
      • Emerging Fields
    • In the Spotlight
      • 40 Years of Erwin Schrödinger Fellowships
      • Quantum Austria
    • Dialogs and Talks
      • think.beyond Summit
    • E-Book Library
  • Go to overview page Funding

    • Portfolio
      • excellent=austria
        • Clusters of Excellence
        • Emerging Fields
      • Projects
        • Principal Investigator Projects
        • Principal Investigator Projects International
        • Clinical Research
        • 1000 Ideas
        • Arts-Based Research
        • FWF Wittgenstein Award
      • Careers
        • ESPRIT
        • FWF ASTRA Awards
        • Erwin Schrödinger
        • Elise Richter
        • Elise Richter PEEK
        • doc.funds
        • doc.funds.connect
      • Collaborations
        • Specialized Research Groups
        • Special Research Areas
        • Research Groups
        • International – Multilateral Initiatives
        • #ConnectingMinds
      • Communication
        • Top Citizen Science
        • Science Communication
        • Book Publications
        • Digital Publications
        • Open-Access Block Grant
      • Subject-Specific Funding
        • AI Mission Austria
        • Belmont Forum
        • ERA-NET HERA
        • ERA-NET NORFACE
        • ERA-NET QuantERA
        • ERA-NET TRANSCAN
        • Alternative Methods to Animal Testing
        • European Partnership Biodiversa+
        • European Partnership ERA4Health
        • European Partnership ERDERA
        • European Partnership EUPAHW
        • European Partnership FutureFoodS
        • European Partnership OHAMR
        • European Partnership PerMed
        • European Partnership Water4All
        • Gottfried and Vera Weiss Award
        • netidee SCIENCE
        • Herzfelder Foundation Projects
        • Quantum Austria
        • Rückenwind Funding Bonus
        • Zero Emissions Award
      • International Collaborations
        • Belgium/Flanders
        • Germany
        • France
        • Italy/South Tyrol
        • Japan
        • Luxembourg
        • Poland
        • Switzerland
        • Slovenia
        • Taiwan
        • Tyrol–South Tyrol–Trentino
        • Czech Republic
        • Hungary
    • Step by Step
      • Find Funding
      • Submitting Your Application
      • International Peer Review
      • Funding Decisions
      • Carrying out Your Project
      • Closing Your Project
      • Further Information
        • Integrity and Ethics
        • Inclusion
        • Applying from Abroad
        • Personnel Costs
        • PROFI
        • Final Project Reports
        • Final Project Report Survey
    • FAQ
      • Project Phase PROFI
        • Accounting for Approved Funds
        • Labor and Social Law
        • Project Management
      • Project Phase Ad Personam
        • Accounting for Approved Funds
        • Labor and Social Law
        • Project Management
      • Expiring Programs
        • FWF START Awards
  • Go to overview page About Us

    • Mission Statement
    • FWF Video
    • Values
    • Facts and Figures
    • Annual Report
    • What We Do
      • Research Funding
        • Matching Funds Initiative
      • International Collaborations
      • Studies and Publications
      • Equal Opportunities and Diversity
        • Objectives and Principles
        • Measures
        • Creating Awareness of Bias in the Review Process
        • Terms and Definitions
        • Your Career in Cutting-Edge Research
      • Open Science
        • Open Access Policy
          • Open Access Policy for Peer-Reviewed Publications
          • Open Access Policy for Peer-Reviewed Book Publications
          • Open Access Policy for Research Data
        • Research Data Management
        • Citizen Science
        • Open Science Infrastructures
        • Open Science Funding
      • Evaluations and Quality Assurance
      • Academic Integrity
      • Science Communication
      • Philanthropy
      • Sustainability
    • History
    • Legal Basis
    • Organization
      • Executive Bodies
        • Executive Board
        • Supervisory Board
        • Assembly of Delegates
        • Scientific Board
        • Juries
      • FWF Office
    • Jobs at FWF
  • Go to overview page News

    • News
    • Press
      • Logos
    • Calendar
      • Post an Event
      • FWF Informational Events
    • Job Openings
      • Enter Job Opening
    • Newsletter
  • Discovering
    what
    matters.

    FWF-Newsletter Press-Newsletter Calendar-Newsletter Job-Newsletter scilog-Newsletter

    SOCIAL MEDIA

    • LinkedIn, external URL, opens in a new window
    • Twitter, external URL, opens in a new window
    • Facebook, external URL, opens in a new window
    • Instagram, external URL, opens in a new window
    • YouTube, external URL, opens in a new window

    SCILOG

    • Scilog — The science magazine of the Austrian Science Fund (FWF)
  • elane login, external URL, opens in a new window
  • Scilog external URL, opens in a new window
  • de Wechsle zu Deutsch

  

ExTrAct-AML

ExTrAct-AML

Kaan Boztug (ORCID: 0000-0001-8387-9185)
  • Grant DOI 10.55776/KLI1056
  • Funding program Clinical Research
  • Status ongoing
  • Start October 1, 2022
  • End September 30, 2025
  • Funding amount € 596,074
  • E-mail

Disciplines

Biology (20%); Computer Sciences (20%); Medical-Theoretical Sciences, Pharmacy (60%)

Keywords

    Precision medicine, Pediatric Oncology, Acute Myeloid Leukemia, Cancer Therapy, Clinical Care, Data Integration

Abstract

Precision medicine aims at delivering the best treatment to an individual patient based on their unique characteristics. In recent years precision medicine approaches have largely been reliant on characterizing patients genomes to identify promising medicines for individuals and defined patient subgroups. These approaches have led to selected success stories. However, childhood cancers have not yet profited as much from such approaches, which is mainly due to their rarity and their distinct genetic profiles. One particular disease in need of more personalized treatments is pediatric acute myeloid leukemia (pedAML) a rare childhood blood cancer with poor outcome. Survival of pedAML patients has increased drastically over the recent decades by optimizing treatment in large international trials, but the improvements in survival rates have slowed down in recent years. Treating pedAML patients based on their genetic profiles can only partially improve this situation, because there are no targeting medicines for most mutations in this disease. To tackle this challenge and ultimately improve outcome in pedAML, we set up a scientific partnership between the St. Anna Childrens Cancer Research Institute and the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences. In this team, we aim to perform comprehensive ex-vivo functional profiling of pedAML patients and their tumors. It allows us to test a many different medicines on individual patients by performing these tests on the tumor outside of the patients body. By additionally profiling the genetic makeup of the tumor and its internal signaling pathways, we aim to create a comprehensive map of promising medicines in pedAML where the genetic and signaling information allows us to understand why these medicines may work in individual patients and specific subgroups. We aim to first perform this profiling on samples from patients diagnosis, but then also characterize how these profiles change over time as patients are treated. With this approach, we hope to better understand the causes of poor treatment response in individual patients and specific subgroups. Additionally, we aim to establish this characterization as a tool to identify patients at risk early on and to be able to assign high-risk patients to promising trials early on, to improve their chances of survival.

Research institution(s)
  • CeMM – Forschungszentrum für Molekulare Medizin GmbH - 27%
  • St. Anna Kinderkrebsforschung GmbH - 73%
Project participants
  • Giulio Gino Maria Superti-Furga, CeMM – Forschungszentrum für Molekulare Medizin GmbH , associated research partner

Discovering
what
matters.

Newsletter

FWF-Newsletter Press-Newsletter Calendar-Newsletter Job-Newsletter scilog-Newsletter

Contact

Austrian Science Fund (FWF)
Georg-Coch-Platz 2
(Entrance Wiesingerstraße 4)
1010 Vienna

office(at)fwf.ac.at
+43 1 505 67 40

General information

  • Job Openings
  • Jobs at FWF
  • Press
  • Philanthropy
  • scilog
  • FWF Office
  • Social Media Directory
  • LinkedIn, external URL, opens in a new window
  • Twitter, external URL, opens in a new window
  • Facebook, external URL, opens in a new window
  • Instagram, external URL, opens in a new window
  • YouTube, external URL, opens in a new window
  • Cookies
  • Whistleblowing/Complaints Management
  • Accessibility Statement
  • Data Protection
  • Acknowledgements
  • Social Media Directory
  • © Österreichischer Wissenschaftsfonds FWF
© Österreichischer Wissenschaftsfonds FWF